Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning

被引:23
|
作者
Luo, B [1 ]
Nanji, SA [1 ]
Schur, CD [1 ]
Pawlick, RL [1 ]
Anderson, CC [1 ]
Shapiro, AMJ [1 ]
机构
[1] Univ Alberta, Clin Islet Transplant Program, Surg Med Res Inst, Dept Surg, Edmonton, AB T6G 2C8, Canada
关键词
bone marrow transplantation; mixed chimerism; tolerance induction; islet transplantation;
D O I
10.1097/01.tp.0000167724.38038.ae
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Whether mixed chimeras induced by nonmyeloablative conditioning are tolerant to challenge with donor allogeneic islet grafts is unknown. Here we investigate whether our nonmyeloablative, costimulation blockade-free and sirolimus (SRL)-based protocol could facilitate mixed chimerism via bone marrow transplantation (BMT) and induce islet allograft tolerance. Methods. After low dose (1-3 Gy) total body irradiation (TBI, day-1), with or without prior lymphocyte depletion, C57BL/6 mice were transfused with 40 X 10(6) BALB/c bone marrow cells (day 0) and received SRL (3 mg/kg/day) for 4 weeks. Chimerism was monitored by flow cytometry and the recipients were rendered diabetic chemically and challenged with donor islets. Results. Mixed chimerism was achieved in mice treated with TBI 3Gy/SRL but it declined over time in 60% (9/15) of them. Long-term stable chimerism was established in 100% of recipients over 50 weeks with either antilymphocyte serum (ALS, 9/9), anti-CD4 (4/4), or anti-CD4 plus anti-CD8 (5/5) prior to BMT. TBI conditioning could be reduced to I Gy, with 90% (9/10) maintaining chimerism in the long-term. When TBI was substituted with cyclophosphamide (CTX) or busulfan (BUS), all mice remained chimeric in the long-term. The chimeras showed no proliferative response to donor antigen and accepted both first and second donor-specific islet grafts indefinitely while rejecting third-party grafts. Conclusions. This data provides the first evidence that stable fully allogeneic chimeras induced with BMT after nonmyeloablative conditioning with SRL and lymphocyte-depleting antibodies exhibit robust donor-specific tolerance to islet grafts.
引用
收藏
页码:370 / 377
页数:8
相关论文
共 46 条
  • [31] Elimination of the maternally induced adaptive immune response allows uniform achievement of high level allogeneic chimerism by in utero hematopoietic cell transplantation and postnatal minimal conditioning BMT
    Santore, Matthew T.
    Merianos, Demetri J.
    Todorow, Carlyn A.
    Flake, Alan W.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 211 (03) : S92 - S92
  • [32] ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms
    Luo, Xunrong
    Pothoven, Kathryn L.
    McCarthy, Derrick
    DeGutes, Mathew
    Martin, Aaron
    Gettss, Daniel R.
    Xia, Guliang
    He, Jie
    Zhang, Xiaomin
    Kaufman, Dixon B.
    Miller, Stephen D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (38) : 14527 - 14532
  • [33] Mixed bone marrow chimerism induced with a non-myeloablative conditioning regimen leads to tolerance of recipient T cells to donor islet grafts and cure of autoimmune diabetes.
    Nikolic, B
    Leykin, I
    Smith, RN
    Sykes, M
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S81 - S82
  • [34] Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving non-myeloablative conditioning and a haploidentical related allogeneic bone marrow transplant
    Toh, HC
    Spitzer, TR
    Preffer, F
    Alexander, SI
    McAfee, S
    Dombkowski, D
    Clark, JS
    Colby, C
    Saidman, S
    Sackstein, R
    Sykes, M
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 2002, 7 (02) : 43 - 47
  • [35] IMPORTANCE OF INTRATHYMIC MIXED CHIMERISM FOR MAINTENANCE OF SKIN ALLOGRAFT TOLERANCE ACROSS FULLY ALLOGENEIC (ENTIRE MAJOR H-2 PLUS MULTIMINOR HISTOCAMPATIBILITY) ANTIGEN BARRIERS IN MICE
    ETO, M
    NISHIMURA, Y
    KONG, YY
    MAEDA, T
    NOMOTO, K
    KUMAZAWA, J
    NOMOTO, K
    TRANSPLANTATION PROCEEDINGS, 1994, 26 (02) : 841 - 844
  • [36] The use of postnatal minimal conditioning bone marrow transplantation to achieve high-level chimerism and donor specific tolerance after in utero hematopoietic cell transplantation in the canine model
    Heaton, Todd E.
    Peranteau, William H.
    Bauer, Thomas R.
    Zoltick, Philip W.
    Hickstein, Dennis D.
    Flake, Alan W.
    EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : S65 - S65
  • [37] Graft versus leukemia effect after related and unrelated allogeneic hematopoietic stem cell transplants (HSCT) in patients with acute myeloid leukemia (AML) following minimal conditioning.
    Hegenbart, U
    Sandmaier, B
    Lange, T
    Poenisch, W
    Maris, M
    Maloney, D
    Leiblein, S
    Deininger, MW
    Al-Ali, HK
    Kliem, C
    Becker, C
    Hartung, G
    Moeckel, J
    Chauncey, T
    Uharek, L
    Greinix, H
    Niederwieser, D
    Storb, R
    BLOOD, 2001, 98 (11) : 672A - 672A
  • [38] Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide
    Tomita, Y
    Yoshikawa, M
    Zhang, QW
    Shimizu, I
    Okano, S
    Iwai, T
    Yasui, H
    Nomoto, K
    JOURNAL OF IMMUNOLOGY, 2000, 165 (01): : 34 - 41
  • [39] Minimal residual disease and chimerism kinetics in B-cell chronic lymphocytic leukaemia after reduced-intensity conditioning regimen allogeneic peripheral blood stem cell transplantation: a case report
    Plesa, A.
    Dubois, V.
    Nicolini, F.
    Mollet, I.
    Revesz, D.
    Maloum, K.
    Dumontet, C.
    Michallet, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S316 - S317
  • [40] Allogeneic mixed chimerism induced by non-myeloablative regimen consisting of co-stimulatory blockade-based minimum intensity conditioning and BMT achieved curative functional reconstitution in X-CGD mouse model
    Takeuchi, Y.
    Otsu, M.
    Takeuchi, E.
    Higashihara, M.
    Abe, M.
    Nakauchi, H.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S276 - S276